Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sufentanil Citrate in Vaso-occlusive crisis: NCT04076748 Clinical Landscape Report 2026
16 October 2026
NCT04076748 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bersiporocin hydrochloride in Idiopathic Pulmonary Fibrosis: ACTRN12619001239156 Clinical Landscape Report 2026
16 October 2026
ACTRN12619001239156 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Concizumab-mtci in Hemophilia B: NCT04082429 Clinical Landscape Report 2026
16 October 2026
NCT04082429 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Concizumab-mtci in Hemophilia B: NCT04083781 Clinical Landscape Report 2026
16 October 2026
NCT04083781 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: ISRCTN15587630 Clinical Landscape Report 2026
16 October 2026
ISRCTN15587630 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
γ-globin gene therapy(CSL Behring LLC) in Acute Chest Syndrome: NCT04091737 Clinical Landscape Report 2026
16 October 2026
NCT04091737 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Crizanlizumab-TMCA in Hematologic Diseases: PACTR201909828957937 Clinical Landscape Report 2026
16 October 2026
PACTR201909828957937 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albutrepenonacog alfa in Hemophilia B: NCT04108260 Clinical Landscape Report 2026
16 October 2026
NCT04108260 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Brogidirsen in Muscular Dystrophy, Duchenne: NCT04129294 Clinical Landscape Report 2026
16 October 2026
NCT04129294 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zilucoplan in Myasthenia Gravis: NCT04115293 Clinical Landscape Report 2026
16 October 2026
NCT04115293 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dalnacogene ponparvovec in Hemophilia B: NCT04135300 Clinical Landscape Report 2026
16 October 2026
NCT04135300 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ketamine Hydrochloride in Vaso-occlusive crisis: NCT04150757 Clinical Landscape Report 2026
16 October 2026
NCT04150757 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.